Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17637 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2023. Written by Selena Z Kuo and 9 co-authors. Institution: NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease. Cited 23 times so far (Crossref); 33 references. The full text is freely available in PubMed Central. Funded by: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.
Topics: Diabetes mellitus
Abstract (original language)
Background
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are independent risk factors for cardiovascular disease (CVD).
Aims
To examine the clinical utility of liver fat quantification for determining CVD risk among a well‐phenotyped cohort of patients with T2DM.
Methods
This was a cross‐sectional analysis of a prospective cohort of adults aged ≥50 with T2DM. Liver fat was quantified with magnetic resonance imaging proton‐density‐fat‐fraction (MRI‐PDFF), an advanced imaging‐based biomarker. Patients were stratified into a higher liver fat group (MRI‐PDFF ≥ 14.6%), and a lower liver fat group (MRI‐PDFF < 14.6%). The co‐primary outcomes were CVD risk determined by Framingham and Atherosclerotic Cardiovascular Disease (ASCVD) risk scores. High CVD risk was defined by risk scores ≥20%.
Results
Of the 391 adults (66% female) in this study, the mean (±SD) age was 64 (±8) years and BMI 30.8 (±5.2) kg/m 2 , respectively. In multivariable analysis, adjusted for age, gender, race, and BMI, patients in the higher liver fat group had higher CVD risk [OR = 4.04 (95% CI: 2.07–7.88, p < 0.0001)] and ASCVD risk score [OR = 2.85 (95% CI: 1.19–6.83, p = 0.018)], respectively.
Conclusion
Higher liver fat content increases CVD risk independently of age, gender, ethnicity and BMI. These findings raise the question whether liver fat quantification should be incorporated into risk calculators to further stratify those with higher CVD risk.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
- Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
- Division of Cardiovascular Medicine, Department of Medicine, University of California at San Diego, La Jolla, California, USA.
ORCID profiles: Jinho Jung, Daniel Q Huang, Rohit Loomba
Funding
- NCATS NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
- NIAAA NIH HHS
- National Center for Advancing Translational Sciences
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Alcohol Abuse and Alcoholism
Cite
APA
Kuo, S. Z., Cepin, S., Bergstrom, J., Siddiqi, H., Jung, J., Lopez, S., Huang, D. Q., Taub, P., Amangurbanova, M., & Loomba, R. (2023). Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17637
Vancouver
Kuo SZ, Cepin S, Bergstrom J, Siddiqi H, Jung J, Lopez S, et al. Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17637
BibTeX
@article{Kuo2023,
author = {Kuo, Selena Z and Cepin, Sandra and Bergstrom, Jaclyn and Siddiqi, Harris and Jung, Jinho and Lopez, Scarlett and Huang, Daniel Q and Taub, Pam and Amangurbanova, Maral and Loomba, Rohit},
title = {Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17637}
}
EUVIMED